Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
May 09 2016 - 1:23PM
Edgar (US Regulatory)
|
|
OMB APPROVAL
|
|
|
OMB Number:
|
3235-0167
|
|
|
Expires:
|
March 31, 2018
|
|
|
Estimated average burden hours per response 1.50
|
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION
12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number:
000-28347
OncoVista Innovative Therapies, Inc.
(Exact name of registrant as specified in its
charter)
14785 Omicron Drive, Suite 104, San Antonio, Texas 78245
(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive offices)
Common stock, $0.001 par value
(Title of each class of securities covered by
this Form)
(Titles of all other classes of securities for
which a duty to file reports under section 13(a) or 15(d) remains)
Please
place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file
reports:
|
|
Rule 12g-4(a)(1)
|
x
|
|
|
Rule 12g-4(a)(2)
|
o
|
|
|
Rule 12h-3(b)(1)(i)
|
o
|
|
|
Rule 12h-3(b)(1)(ii)
|
o
|
|
|
Rule 15d-6
|
o
|
|
|
Rule 15d-22(b)
|
o
|
Approximate number of holders of record as of
the certification or notice date: 226
Pursuant
to the requirements of the Securities Exchange Act of 1934 OncoVista Innovative Therapies, Inc.
has caused this certification/notice
to be signed on its behalf by the undersigned duly authorized person.
|
Date: May 4, 2016
|
OncoVista Innovative Therapies, Inc.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Alexander L. Weis
|
|
|
Name:
|
Alexander L. Weis
|
|
|
Title:
|
Chief Executive Officer
|
Instruction:
This form is required by Rules 12g-4, 12h-3 and 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange
Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It
may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person
signing the form shall be typed or printed under the signature.
OncoVista Innovative The... (CE) (USOTC:OVIT)
Historical Stock Chart
From Nov 2024 to Dec 2024
OncoVista Innovative The... (CE) (USOTC:OVIT)
Historical Stock Chart
From Dec 2023 to Dec 2024
